MNG1085
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.481
- INTERFERON_GAMMA_RESPONSE+0.445
- PROTEIN_SECRETION+0.433
- TNFA_SIGNALING_VIA_NFKB+0.410
- CHOLESTEROL_HOMEOSTASIS+0.387
- INFLAMMATORY_RESPONSE+0.378
- UV_RESPONSE_DN+0.368
- ANDROGEN_RESPONSE+0.363
- TGF_BETA_SIGNALING+0.362
- MYC_TARGETS_V1+0.325
Top 10 suppressed
- KRAS_SIGNALING_DN-0.213
- WNT_BETA_CATENIN_SIGNALING-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.163
- SPERMATOGENESIS-0.141
- MYC_TARGETS_V2-0.125
- HEDGEHOG_SIGNALING-0.067
- MYOGENESIS-0.064
- ANGIOGENESIS-0.044
- OXIDATIVE_PHOSPHORYLATION-0.033
- BILE_ACID_METABOLISM-0.015
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NR9FRY5T | Schwannoma | — | 0.867 |
| 2 | MNG1215 | — | — | 0.863 |
| 3 | SRR934871 | — | — | 0.854 |
| 4 | BS_JK0VPG1T | Schwannoma | — | 0.846 |
| 5 | SRR6013563 | — | cohortMD2 | 0.844 |
| 6 | E5FB107A-9555-419F-84BF-2A59873104B9 | — | — | 0.843 |
| 7 | BS_J4GQPZS0 | Schwannoma | — | 0.840 |
| 8 | SRR934811 | — | — | 0.837 |
| 9 | SRR934833 | — | — | 0.832 |
| 10 | SRR12696731 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.481 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.445 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.433 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.387 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.378 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.368 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.363 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.362 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.325 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.311 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.283 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.279 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.232 | Idelalisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.218 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.211 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.191 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.189 | Inavolisib | — uncovered |
| COMPLEMENT | 0.187 | Inavolisib | — uncovered |